These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 28485352)

  • 21. Prospective comparison of outcome after treatment for triple-negative and non-triple-negative breast cancer.
    Joyce DP; Murphy D; Lowery AJ; Curran C; Barry K; Malone C; McLaughlin R; Kerin MJ
    Surgeon; 2017 Oct; 15(5):272-277. PubMed ID: 28277293
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Breast cancer with triple-negative phenotype in the Russian patient population. Clinical and morphologic features].
    Zhukova LG
    Vopr Onkol; 2015; 61(2):189-94. PubMed ID: 26087596
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulator of G protein signaling 20 correlates with clinicopathological features and prognosis in triple-negative breast cancer.
    Li Q; Jin W; Cai Y; Yang F; Chen E; Ye D; Wang Q; Guan X
    Biochem Biophys Res Commun; 2017 Apr; 485(3):693-697. PubMed ID: 28237701
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic significance of proline, glutamic acid, leucine rich protein 1 (PELP1) in triple-negative breast cancer: a retrospective study on 129 cases.
    Zhang Y; Dai J; McNamara KM; Bai B; Shi M; Chan MS; Liu M; Sasano H; Wang X; Li X; Liu L; Ma Y; Cao S; Xing Y; Zhao B; Song Y; Wang L
    BMC Cancer; 2015 Oct; 15():699. PubMed ID: 26472563
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Imbalance in leptin-adiponectin levels and leptin receptor expression as chief contributors to triple negative breast cancer progression in Northeast India.
    Sultana R; Kataki AC; Borthakur BB; Basumatary TK; Bose S
    Gene; 2017 Jul; 621():51-58. PubMed ID: 28414093
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk factors for distant metastasis of patients with primary triple-negative breast cancer.
    Yao Y; Chu Y; Xu B; Hu Q; Song Q
    Biosci Rep; 2019 Jun; 39(6):. PubMed ID: 31113872
    [No Abstract]   [Full Text] [Related]  

  • 27. Impact of Detection Method and Age on Survival Outcomes in Triple-Negative Breast Cancer: A Population-Based Cohort Analysis.
    Rayson D; Payne JI; Michael JCR; Tsuruda KM; Abdolell M; Barnes PJ
    Clin Breast Cancer; 2018 Oct; 18(5):e955-e960. PubMed ID: 29885790
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Opportunities for improving triple-negative breast cancer outcomes: results of a population-based study.
    Rapiti E; Pinaud K; Chappuis PO; Viassolo V; Ayme A; Neyroud-Caspar I; Usel M; Bouchardy C
    Cancer Med; 2017 Mar; 6(3):526-536. PubMed ID: 28211614
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of patients with node-negative, triple-negative breast cancer who benefit from adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy.
    Wu CE; Chen SC; Lin YC; Lo YF; Hsueh S; Chang HK
    Anticancer Res; 2014 Mar; 34(3):1301-6. PubMed ID: 24596377
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of epithelial-mesenchymal transition-related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome.
    Jang MH; Kim HJ; Kim EJ; Chung YR; Park SY
    Hum Pathol; 2015 Sep; 46(9):1267-74. PubMed ID: 26170011
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TNBC vs non-TNBC: A retrospective review of differences in mean age, family history, smoking history, and stage at diagnosis.
    Tariq K; Farhangi A; Rana F
    Clin Adv Hematol Oncol; 2014 Jun; 12(6):377-81. PubMed ID: 25003567
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
    Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
    Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
    Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
    Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Platinum-based chemotherapy in triple-negative advanced breast cancer.
    Villarreal-Garza C; Khalaf D; Bouganim N; Clemons M; Peña-Curiel O; Baez-Revueltas B; Kiss A; Kassam F; Enright K; Verma S; Pritchard K; Myers J; Dent R
    Breast Cancer Res Treat; 2014 Aug; 146(3):567-72. PubMed ID: 25001611
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinicopathological Profiles of and Patterns of Recurrence in Triple-Negative Breast Cancer Patients at a Cancer Care Center in Southern India.
    Inampudi P; Yadlapalli DC; Gullipalli M
    Cureus; 2024 Jul; 16(7):e63886. PubMed ID: 39099998
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BCL2 is an independent predictor of outcome in basal-like triple-negative breast cancers treated with adjuvant anthracycline-based chemotherapy.
    Bouchalova K; Svoboda M; Kharaishvili G; Vrbkova J; Bouchal J; Trojanec R; Koudelakova V; Radova L; Cwiertka K; Hajduch M; Kolar Z
    Tumour Biol; 2015 Jun; 36(6):4243-52. PubMed ID: 25616695
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Comparison of biological behavior between triple-negative breast cancer and non-triple- negative breast cancer].
    Ma JG; Wang NJ; Yu WJ
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 Oct; 31(10):1729-32. PubMed ID: 22027778
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
    Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
    Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Triple-negative breast cancer: analysis of patients diagnosed and/or treated at the Masaryk Memorial Cancer Institute between 2004 and 2009].
    Svoboda M; Navrátil J; Fabian P; Palácová M; Gombošová J; Slámová L; Princ D; Syptáková B; Kudláček A; Bílek O; Pospíšil P; Kazda T; Grell P; Poprach A; Selingerová I; Nenutil R; Juráček J; Héžová R; Slabý O; Vyzula R
    Klin Onkol; 2012; 25(3):188-98. PubMed ID: 22724568
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlation between epidermal growth factor receptor and tumor stem cell markers CD44/CD24 and their relationship with prognosis in breast invasive ductal carcinoma.
    Zheng Z; Shao N; Weng H; Li W; Zhang J; Zhang L; Yang L; Ye S
    Med Oncol; 2015 Jan; 32(1):275. PubMed ID: 25429827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.